Sort   by:  
 Page size 
UnknownRmpA2, an activator of capsule biosynthesis in Klebsiella pneumoniae CG43, regulates K2 cps gene expression at the transcriptional level.
Not available
S-EPMC142793 | biostudies-literature
ProteomicsO-GlcNAc proteome of invasive ductal breast carcinomas
O-GlcNAc proteins in LNM and non-LNM breast tumors of IDCs were identified by using the strategy of chemo-enzymatic labeling in combination with click chemistry and LC-MS/MS.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-03-29 | MSV000080753 | MassIVE
UnknownMulti-omic profiling reveals age-related immune dynamics in healthy adults.
Not available
S-EPMC12711581 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownSystemic inflammation and lymphocyte activation precede rheumatoid arthritis.
Not available
S-EPMC11565773 | biostudies-literature
UnknownLong-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownEmpagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7614055 | biostudies-literature
Sort   by:  
 Page size